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variation. Detailed values for the PTV and OAR can be found in table 
1. 
 
  
Conclusions: The Eclipse planning system is able to achieve a 
comparable plan quality for Elekta VMAT delivery technique to that of 
fixed field IMRT in terms of target coverage and critical structure 
sparing using optimizing templates without operator interference. 
Plans with 2 arcs show less exceeding of the objectives than plans 
with 1 arc. In the VMAT cases where the objectives are not met, 
adapting the optimizing parameters once results in an improvement of 
the target coverage and OAR sparing.  
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Purpose/Objective: Many indications suggest that a dose escalation in 
prostate carcinoma treatment could improve the disease local control. 
Several methods are developed to reduce the rectal volume involved 
in high doses since rectal toxicity is one of main aspects limiting the 
prescribed dose. One possible strategy is to insert between rectum 
and prostate walls a little balloon. This study aims to assess the 
efficacy of this experimental device in reducing rectal dose in 
prostate EBRT. 
Materials and Methods: 9 patients with prostate carcinoma were 
recruited in 2010 at the Oncology Institute of Veneto (Padova, Italy) 
for a 'one-arm' multicenter study to evaluate the use of a 
biodegradable implantable balloon in term of efficacy and safety. The 
balloon is made of co-polymer Poly(L-lactide-co-ε-caprolactone). After 
the implantation between prostate and rectum anterior wall the 
balloon is filled with physiological solution. It remains in situ at least 
the whole radiation treatment time. Every patient had a CT scan 
(CT1) before the implantation and one after (CT2). The last one was 
used for plan optimization. A mean of 4 CT scans were acquired for 
every patient during treatment to assess the stability of the device. 3 
treatment plans were calculated on CT1 and CT2:  
1. a 6 fields standard 3DCRT (the one actually delivered). 
2. a 7 fields 3DCRT technique. 
3. a 7 fields IMRT. 
The prescribed dose was D95=78 Gy in 39 fractions. D50, V75, V70, 
V65, V60, V50 and V78 rectum DVH points were evaluated. QUANTEC 
dose limits were also verified. 3DCRT plans calculated on CT2 were 
compared with the IMRT plans calculated on CT1 to evaluate the 
device efficacy instead a highly conformance technique. A t-test was 
used to evaluate the statistic significance between plans. 
Results: Dose analysis shows implant efficacy for both 6 and 7 fields 
3DCRT techniques. DVHs comparison shows a 40 % and 55% mean 
reduction in V50 and V60 values. D50 decreases from 54,95 Gy to 
44,26 Gy for the 6 fields 3DCRT with a reduction of 18% (p <= 0.01) 
and from 49.6 Gy to 38.8 Gy for the 7 fields 3DCRT with a reduction of 
21% (p <= 0.01). Balloon allows the right QUANTEC dose-volume 
constraints in 7 out of 9 patients. A significant reduction of V78 mean 
value is observed, passing from a 4.0 cc to 1.2 cc.  IMRT technique 
shows insignificant differences between cases. D50 is reduced of 3% 
while V78 remains about 1cc for both cases. QUANTEC limits are 
independently reached using IMRT. Dose comparison between 3DCRT 
techniques with balloon and IMRT technique without doesn’t show a 
clear advantage in using the experimental device. 
Conclusions: Our dosimetric study clearly shows the efficacy of the 
implantable device reducing rectal dose in case of 3DCRT techniques. 
IMRT technique with no device is comparable with the 3DCRT with 
device. 
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Purpose/Objective: To compare plan quality in terms of dosimetric 
homogeneity, target conformity, organ-at-risk (OAR) sparing, monitor 
unit (MU) usage, and beam-on time for eleven stereotactic 
radiosurgery patients using RapidArc™ volumetric- modulated 
arctherapy (VMAT) with both standard and flattening filter free 
modes. Plans where calculated with both a standard120 leaf MLC and 
a HD120 MLC. 
Materials and Methods: Eleven patients with one or more brain 
metastases underwent computed tomography simulation. Treatment 
planning was performed using Varian Eclipse ™ v10.0.39 to generate 
four 2-arc RapidArc plans.Each patient was planned with FFF and 
flattened mode with both a standard and high definition MLC. All 
plans were calculated to deliver the same mean dose tothe PTV. Plans 
were created with dose control tuning structures surrounding targets 
to maximize conformity and dose gradient. Dosimetric parameters 
used for target analysis were RTOG conformity index (CIRTOG), 
homogeneity index (HIRTOG), inverse Paddick Conformity Index(PCI) 
and D5–D95. OAR sparing was analyzed in terms of Dmax and D10cc for 
brain. Treatment delivery was evaluated based on measured beam-on 
times delivered on a Varian Truebeam, Varian Truebeam STx and 
Varian Clinac iX linear accelerators. 
Results: Dosimetric conformity, homogeneity, and OAR sparing were 
comparable when using the HDMLC irrespective of mode for all 
patients. The Paddick Conformity Index was inferior for the standard 
MLC plans than the HDMLC with the mean decreasing from 4.3(±1.2) 
to 3.8(± 0.7). The PTV homogeneity index was inferior for the 
standard MLC than the HDMLC plans, decreasing from 3.3(± 0.8) to 
2.4(± 0.7). Mean beam-on times for FFF mode and flattened mode 
were 3(±0.7) and 12(±2.4) minutes, respectively. Mean MUs were 6760 
and 7015, respectively.  
Conclusions: Dosimetric conformity, homogeneity, and OAR sparing 
were similar when planned with a HDMLC. There was some reduction 
in conformality when planned with a standard MLC. Conformality was 
independent of treatment mode. The use of FFF resulted in 
substantially less beam-on time and fewer MUs than standard mode. 
The rapid delivery of SRS with an HDMLC and FFF improved workflow 
on the linac and limited the potential for intra-fraction organ and 
patient motion, which can cause dosimetric errors  
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Purpose/Objective: It has previously been reported that VMAT 
reduces the overall treatment time for lung SABR compared to 
conformal therapy techniques. This study investigates whether the 
increased dose-rate available with Flattening-Filter Free (FFF) beams 
can be used to further decrease delivery times. An analysis was also 
made of FFF plan quality relative to standard (flattened-beam) plans. 
Materials and Methods: 5 patients were planned for lung SABR with a 
dose of 55Gy in 5 fractions. VMAT plans with flattened 6MV beams(6X) 
and flattening filter free (6XFFF) were compared. The 6XFFF beam 
energy was tuned so that dose was matched to the flattened 6X beam 
energy at a depth of 10cm in water. All planning was performed with 
Monaco v3.3*1 for delivery on a Synergy*1 Linac with AgilityTM head. An 
isocentre positioned at the patient mid-line was used for all plans. 
Treatment deliveries were verified using the Delta4*2 phantom and 
chamber measurements in a CIRS*3 lung phantom. Plans were 
compared in terms of measured delivery time, gamma index and PTV 
point dose. 
Results: Plans produced with both 6X and 6XFFF had comparable plan 
quality (Table 1) and were produced in a similar time-frame.The VMAT 
prescription class solution used clinically for 6X treatments did not 
require alteration when planned with 6XFFF. Dose deliveries for both 
